Owlet (OWLT) Competitors

Cytek Biosciences (NASDAQ:CTKB) and Owlet (NYSE:OWLT) are both small-cap measuring and control equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

Does the media favor CTKB or OWLT?

In the previous week, Owlet had 3 more articles in the media than Cytek Biosciences. MarketBeat recorded 4 mentions for Owlet and 1 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 1.46 beat Owlet's score of 0.21 indicating that Cytek Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Owlet	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders and institutionals have more ownership in CTKB or OWLT?

69.5% of Cytek Biosciences shares are held by institutional investors. Comparatively, 72.6% of Owlet shares are held by institutional investors. 10.3% of Cytek Biosciences shares are held by company insiders. Comparatively, 67.1% of Owlet shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Which has higher valuation and earnings, CTKB or OWLT?

Cytek Biosciences has higher revenue and earnings than Owlet. Cytek Biosciences is trading at a lower price-to-earnings ratio than Owlet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$200.45M	2.63	-$6.02M	-$0.05	-83.00
Owlet	$78.10M	1.64	-$12.54M	-$3.50	-2.15

Which has more risk & volatility, CTKB or OWLT?

Cytek Biosciences has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Owlet has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500.

Do analysts rate CTKB or OWLT?

Cytek Biosciences presently has a consensus price target of $5.60, indicating a potential upside of 34.94%. Owlet has a consensus price target of $10.25, indicating a potential upside of 36.30%. Given Owlet's stronger consensus rating and higher possible upside, analysts clearly believe Owlet is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Owlet	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Is CTKB or OWLT more profitable?

Cytek Biosciences has a net margin of -3.27% compared to Owlet's net margin of -54.45%. Owlet's return on equity of -0.36% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-3.27%	-1.66%	-1.30%
Owlet	-54.45%	-0.36%	-3.26%

Summary

Owlet beats Cytek Biosciences on 9 of the 16 factors compared between the two stocks.